美国Repligen Corporation www.repligen.com
Repligen公司成立于1981年在特拉华州和在纳斯达克上市，交易代码RGEN。该公司的重点是对神经系统疾病的新疗法。发展计划，目前正在对胰腺进行磁共振成像等领域，躁郁症，弗里德的共济失调和脊髓性肌萎缩。此外，Repligen是世界上重组蛋白A的领先供应商的利润来自这有助于支持我们的临床开发项目。

Repligen Corporation was incorporated in 1981 in Delaware and is traded on the NASDAQ under the symbol RGEN. The Company is focused on the development of novel therapeutics for neurological disorders. Development programs are currently being conducted in the areas of pancreatic MRI imaging, bipolar disorder, Friedreich's ataxia and spinal muscular atrophy. In addition, Repligen is the world's leading supplier of recombinant Protein A, the profits from which help to support our clinical development programs. Repligen has also secured a source of revenue through the successful licensing of CTLA4-Ig, and receives royalties from Bristol-Myers Squibb based on their U.S. sales of Orencia® for rheumatoid arthritis. The Company is located in Waltham, Massachusetts and currently has approximately 70 employees. 

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. A number of drug development programs are currently being conducted to evaluate our drug candidates in diseases such as bipolar disorder and Friedreich's ataxia.
We currently market recombinant Protein A, which partially funds the advancement of our product development pipeline while supporting our financial stability. In addition, we secured a source of revenue through the successful licensing of our patent covering the use of CTLA4-Ig, and receive royalties from Bristol-Myers Squibb based on their U.S. sales of Orencia® for rheumatoid arthritis.